{
    "root": "34232f88-5219-6451-e063-6294a90a4469",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "MELOXICAM",
    "value": "20250502",
    "ingredients": [
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "SODIUM CITRATE",
            "code": "1Q73Q2JULR"
        },
        {
            "name": "MELOXICAM",
            "code": "VG2QF83CGL"
        },
        {
            "name": "CELLULOSE, MICROCRYSTALLINE",
            "code": "OP1R32D61U"
        },
        {
            "name": "SODIUM STEARATE",
            "code": "QU7E2XA9TG"
        }
    ],
    "indications": "meloxicam non-steroidal anti-inflammatory indicated : osteoarthritis ( oa ) ( 1.1 ) rheumatoid arthritis ( rheumatoid arthritis ) ( 1.2 ) juvenile rheumatoid arthritis ( jra ) patients weigh ≥60 kg ( 1.3 )",
    "contraindications": "lowest effective dose shortest duration consistent individual patient treatment goals ( 2.1 ) oa ( 2.2 ) rheumatoid arthritis ( 2.3 ) : starting dose : 7.5 mg daily dose may increased 15 mg daily jra ( 2.4 ) : 7.5 mg daily children ≥60 kg meloxicam tablets interchangeable approved formulations oral meloxicam even total milligram strength ( 2.6 )",
    "warningsAndPrecautions": "meloxicam tablets , usp 7.5 mg yellow coloured , round , biconvex tablets , debossed `` 158 `` one side `` c `` . meloxicam tablets , usp 15 mg yellow coloured , round , flat bevelled tablets , debossed `` cipla `` one side `` 159 `` . meloxicam tablets , usp 7.5 mg available follows : ndc 76420-325-20 ( repackaged ndc 69097-158-xx ) bottles 20 ndc 76420-325-30 ( repackaged ndc 69097-158-xx ) bottles 30 ndc 76420-325-60 ( repackaged ndc 69097-158-xx ) bottles 60 ndc 76420-325-90 ( repackaged ndc 69097-158-xx ) bottles 90 ndc 76420-325-01 ( relabeled ndc 69097-158-07 ) bottles 100 ndc 76420-325-05 ( relabeled ndc 69097-158-12 ) bottles 500 ndc 76420-325-00 ( relabeled ndc 69097-158-15 ) bottles 1000 meloxicam tablets , usp 15 mg available follows : ndc 76420-326-20 ( repackaged ndc 69097-159-xx ) bottles 20 ndc 76420-326-30 ( repackaged ndc 69097-159-xx ) bottles 30 ndc 76420-326-60 ( repackaged ndc 69097-159-xx ) bottles 60 ndc 76420-326-90 ( repackaged ndc 69097-159-xx ) bottles 90 ndc 76420-326-01 ( relabeled ndc 69097-159-07 ) bottles 100 ndc 76420-326-05 ( relabeled ndc 69097-159-12 ) bottles 500 ndc 76420-326-00 ( relabeled ndc 69097-159-15 ) bottles 1000 storage store 20°c 25°c ( 68°f 77°f ) [ usp controlled room temperature ] . keep meloxicam tablets dry place . dispense tablets tight container . keep medications reach children .",
    "adverseReactions": "meloxicam contraindicated following patients : known hypersensitivity ( e.g . , anaphylactic serious skin ) meloxicam components product [ ( 5.7 , 5.9 ) ] history asthma , urticaria , allergic-type taking aspirin nsaids . severe , sometimes fatal , anaphylactic nsaids reported patients [ ( 5.7 , 5.8 ) ] setting coronary artery bypass graft ( cabg ) surgery [ ( 5.1 ) ]",
    "indications_original": "Meloxicam is a non-steroidal anti-inflammatory drug indicated for: Osteoarthritis (OA) (1.1) Rheumatoid Arthritis (RA) (1.2) Juvenile Rheumatoid Arthritis (JRA) in patients who weigh ≥60 kg (1.3)",
    "contraindications_original": "Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals ( 2.1 ) OA (2.2) and RA (2.3) : Starting dose: 7.5 mg once daily Dose may be increased to 15 mg once daily JRA (2.4) : 7.5 mg once daily in children ≥60 kg Meloxicam tablets are not interchangeable with approved formulations of oral meloxicam even if the total milligram strength is the same ( 2.6 )",
    "warningsAndPrecautions_original": "Meloxicam tablets, USP 7.5 mg are yellow coloured, round, biconvex tablets, debossed with \"158\" on one side and \"C\" on the other.\n                  Meloxicam tablets, USP 15 mg are yellow coloured, round, flat bevelled tablets, debossed with \"CIPLA\" on one side and \"159\" on the other.\n                  Meloxicam tablets, USP 7.5 mg are available as follows:\n                  NDC 76420-325-20 (repackaged from NDC 69097-158-XX) Bottles of 20\n                  NDC 76420-325-30 (repackaged from NDC 69097-158-XX) Bottles of 30\n                  NDC 76420-325-60 (repackaged from NDC 69097-158-XX) Bottles of 60\n                  NDC 76420-325-90 (repackaged from NDC 69097-158-XX) Bottles of 90\n                  NDC 76420-325-01 (relabeled from NDC 69097-158-07) Bottles of 100\n                  NDC 76420-325-05 (relabeled from NDC 69097-158-12) Bottles of 500\n                  NDC 76420-325-00 (relabeled from NDC 69097-158-15) Bottles of 1000                  \n                  Meloxicam tablets, USP 15 mg are available as follows:\n                  NDC 76420-326-20 (repackaged from NDC 69097-159-XX) Bottles of 20\n                  NDC 76420-326-30 (repackaged from NDC 69097-159-XX) Bottles of 30\n                  NDC 76420-326-60 (repackaged from NDC 69097-159-XX) Bottles of 60\n                  NDC 76420-326-90 (repackaged from NDC 69097-159-XX) Bottles of 90\n                  NDC 76420-326-01 (relabeled from NDC 69097-159-07) Bottles of 100\n                  NDC 76420-326-05 (relabeled from NDC 69097-159-12) Bottles of 500\n                  NDC 76420-326-00 (relabeled from NDC 69097-159-15) Bottles of 1000\n                  \n                     Storage\n                  \n                  Store at 20°C to 25°C (68°F to 77°F) [see USP Controlled Room Temperature]. Keep meloxicam tablets in a dry place.\n                  Dispense tablets in a tight container.\n                  Keep this and all medications out of the reach of children.",
    "adverseReactions_original": "Meloxicam is contraindicated in the following patients:\n                  \n                     Known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to meloxicam or any components of the drug product [\n  \n   see Warnings and Precautions (\n   \n    5.7,\n   \n    5.9)\n  \n   ]\n \n  \n                     History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs. Severe, sometimes fatal, anaphylactic reactions to NSAIDs have been reported in such patients [\n  \n   see Warnings and Precautions (\n   \n    5.7,\n   \n    5.8)\n  \n   ]\n \n  \n                     In the setting of coronary artery bypass graft (CABG) surgery [\n  \n   see Warnings and Precautions (\n   \n    5.1)\n  \n   ]"
}